Prestige Consumer Healthcare (PBH) Projected to Post Earnings on Thursday

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) will likely be announcing its Q4 2025 earnings results before the market opens on Thursday, May 8th. Analysts expect Prestige Consumer Healthcare to post earnings of $1.30 per share and revenue of $289.36 million for the quarter. Prestige Consumer Healthcare has set its FY 2025 guidance at 4.500-4.500 EPS.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The company reported $1.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. On average, analysts expect Prestige Consumer Healthcare to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Prestige Consumer Healthcare Stock Performance

Shares of NYSE PBH traded down $1.22 during mid-day trading on Monday, hitting $82.97. The company had a trading volume of 317,284 shares, compared to its average volume of 291,082. Prestige Consumer Healthcare has a 12 month low of $62.35 and a 12 month high of $90.04. The firm has a market cap of $4.11 billion, a P/E ratio of 19.43, a PEG ratio of 2.69 and a beta of 0.47. The business's 50-day simple moving average is $83.27 and its 200-day simple moving average is $81.03. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.68 and a quick ratio of 2.20.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on PBH. Royal Bank of Canada lifted their price objective on Prestige Consumer Healthcare from $96.00 to $97.00 and gave the stock a "sector perform" rating in a report on Friday, March 21st. StockNews.com upgraded shares of Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research note on Tuesday, April 29th. DA Davidson lifted their target price on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a "buy" rating in a research report on Friday, February 7th. Canaccord Genuity Group increased their price target on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a "buy" rating in a research report on Friday, February 7th. Finally, Oppenheimer lifted their price objective on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an "outperform" rating in a report on Thursday, February 13th. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $93.33.

Insider Transactions at Prestige Consumer Healthcare

In other news, SVP Mary Beth Fritz sold 1,678 shares of Prestige Consumer Healthcare stock in a transaction on Monday, March 10th. The stock was sold at an average price of $90.00, for a total value of $151,020.00. Following the completion of the sale, the senior vice president now directly owns 17,157 shares of the company's stock, valued at approximately $1,544,130. This trade represents a 8.91 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 1.60% of the company's stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.